Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Inflammatory Bowel Disease

Inflammatory Bowel Disease

Subtypes of Inflammatory Bowel Disease

Ulcerative Colitis 30 Crohn's Disease 26

66 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Inflammatory Bowel Disease

68 trials tracked for Inflammatory Bowel Disease: 19 in phase 3 or 4 and 12 with published results. The most-cited published study has 131 citations.

68Trials tracked
19Phase 3 & 4
0Recruiting
12With published results
Phase distribution
Phase 4 9 Phase 3 10 Phase 2 10 Phase 1 6 Other / NA 33
  1. Phase 3 Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2) Completed · 131 cited
  2. Phase 3 Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Ulcerative Colitis (AEGIS-1) Completed · 131 cited
  3. Phase 3 Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD) Completed · 61 cited
  4. Phase 3 A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1) Completed · 40 cited
  5. Phase 3 A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2) Completed · 40 cited
  6. Phase 3 A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI) Completed · 40 cited
Show 44 more trials
  1. Phase 4 Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy Completed · 38 cited
  2. Phase 3 A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis Completed · 38 cited
  3. Phase 4 Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®) Completed · 25 cited
  4. Phase 4 Chronotherapy in Inflammatory Bowel Disease Completed · 11 cited
  5. Phase 4 Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab Completed · 2 cited
  6. Phase 4 Safety of Reduced Infliximab Infusion Time Completed
  7. Phase 4 Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease Completed
  8. Phase 4 Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease Completed
  9. Phase 4 NITI CAR27 (ColonRing) Compression Anastomosis in Colorectal Surgery Completed
  10. Phase 4 Gene Regulation by Thiazolidinediones Completed
  11. Phase 3 Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study Completed
  12. Phase 3 Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD Completed
  13. Phase 3 The Home Telemanagement (UC HAT) Trial for Patients With Ulcerative Colitis Completed
  14. Phase 2 ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI Completed
  15. Phase 2 Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis Completed
  16. Phase 2 A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC Completed
  17. Phase 2 The ICON Study: Outcomes After FMT for Patients With IBD and CDI Completed
  18. Phase 2 A Trial of Rosiglitazone for Ulcerative Colitis Completed
  19. Phase 2 Telemedicine To Provide Inflammatory Bowel Disease Outpatient Care Completed
  20. Phase 2 Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis Completed
  21. Phase 2 Dietary Treatment of Crohn's Disease Completed
  22. Phase 2 Sirolimus for Autoimmune Disease of Blood Cells Completed
  23. Phase 2 Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Dietary Fiber in Patients With Ulcerative Colitis Completed
  24. Phase 1 Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease Completed
  25. Phase 1 Evaluation of the Pharmacokinetics, Safety and Tolerability of Single Dose of PF-06480605 in Chinese Healthy Participants Completed
  26. Phase 1 Vitamin D Supplementation in Crohn's Patients Completed
  27. Phase 1 Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab Completed
  28. Phase 1 Phase 1 Study for IPG11406 in Health Volunteer Completed
  29. Phase 1 Bacteriotherapy in Pediatric Inflammatory Bowel Disease Completed
  30. N/A Assessment of the Social Cost of Crohn's Disease: Economic and Quality of Life Aspects (Study P04560) Completed
  31. N/A Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD) Completed
  32. N/A Perianal Fistula (PAF) Validation and Burden of Illness Study Completed
  33. N/A Feraccru® Real World Effectiveness Study in Hospital Practice ( FRESH ) Completed
  34. N/A Comparison of Capso Vision SV-1 to PillCam SB2 in the Evaluation of Subjects With Suspected Small Bowel Disease Completed
  35. N/A A Study to Evaluate Disease Control, Treatment Patterns, Burden of Disease and Quality of Life in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD) Completed
  36. N/A A Study of Moderate to Severe Inflammatory Bowel Disease, Including Ulcerative Colitis (UC) and Crohn's Disease (CD) Completed
  37. N/A Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes Completed
  38. N/A Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics Completed
  39. N/A Digital Behavioral Interventions in Inflammatory Bowel Disease Completed
  40. N/A Autoimmune Protocol Diet and Inflammatory Bowel Disease Completed
  41. N/A The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study Completed
  42. N/A Stress in Inflammatory Bowel Disease Completed
  43. N/A Specialty Medical Homes to Improve Outcomes for Patients With IBD and Behavioral Health Conditions Completed
  44. N/A A Comparison of Ultrasound Guided Transversus Abdominis Plane Nerve Block Techniques Completed

Showing the 50 most-cited and recently-updated of 68 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Meta-analysis links soft drinks to higher IBD risk, alcohol, coffee, tea to lower risk
Nutrition & Obesity Medicine Meta-analysis
Meta-analysis links soft drinks to higher IBD risk, alcohol, coffee, tea to lower risk Soft drinks linked to higher inflammatory bowel disease risk
This meta-analysis of observational studies examined associations between drink consumption and inflammatory bowel disease risk. Soft bevera…
A large review finds that drinking soft drinks may raise your risk of inflammatory bowel disease, while coffee, tea, and alcohol may lower i…
Frontiers May 20, 2026
Narrative review on vitamin D and VDR in gastrointestinal and pulmonary diseases
Nutrition & Obesity Medicine Sys. Review
Narrative review on vitamin D and VDR in gastrointestinal and pulmonary diseases Vitamin D's Role in Gut and Lung Health Examined
This narrative review synthesizes evidence on vitamin D deficiency and VDR expression across gastrointestinal and pulmonary conditions. The …
A review explores how vitamin D deficiency and VDR expression may influence digestive and respiratory diseases, but more research is needed.
Frontiers May 18, 2026
Meta-analysis of GWAS data identifies genetic risk factors for inflammatory bowel disease in 125,992 individuals
Genetics & Precision Medicine Meta-analysis
Meta-analysis of GWAS data identifies genetic risk factors for inflammatory bowel disease in 125,992 individuals Genetic map reveals new targets for inflammatory bowel disease
This meta-analysis review synthesizes genome-wide association study data from 125,992 individuals with IBD and more than 1.2 million control…
A massive genetic study found 619 new signals linked to Crohn's and ulcerative colitis, offering fresh clues for future treatments.
medRxiv May 18, 2026
Review of dietary polysaccharides for inflammatory bowel disease notes limited clinical evidence
Nutrition & Obesity Medicine Sys. Review
Review of dietary polysaccharides for inflammatory bowel disease notes limited clinical evidence New food fibers may calm gut inflammation and heal the lining
This narrative review examines the role of dietary polysaccharides in managing inflammatory bowel disease. The authors synthesize preclinica…
New research suggests specific dietary fibers might calm gut inflammation and heal the intestinal lining in people with inflammatory bowel d…
Frontiers May 15, 2026
Review: Pregnane X Receptor Regulates Intestinal Homeostasis in Inflammatory Bowel Disease
Allergy & Immunology Sys. Review
Review: Pregnane X Receptor Regulates Intestinal Homeostasis in Inflammatory Bowel Disease Your Gut's Secret Inflammation Brake Just Got Stronger
This narrative review synthesizes evidence from mouse models on the role of the pregnane X receptor (Nr1i2) in inflammatory bowel disease. T…
A gut receptor controls inflammation like a brake pedal People with Crohn's disease or ulcerative colitis Mouse studies mean human treatment…
Frontiers May 12, 2026
FDA Approves Hadlima (adalimumab) for Multiple Inflammatory Indications
Rheumatology FDA Approval
FDA Approves Hadlima (adalimumab) for Multiple Inflammatory Indications FDA approves Hadlima, a new biosimilar for several inflammatory diseases.
The FDA approved Hadlima (adalimumab) for several inflammatory conditions including rheumatoid arthritis, juvenile idiopathic arthritis, pso…
The FDA approved Hadlima (adalimumab) for treating conditions like rheumatoid arthritis, psoriasis, and Crohn's disease. It is a biosimilar,…
FDA May 5, 2026
Meta-analysis associates childhood antibiotic use with increased inflammatory bowel disease risk
Infectious Disease Meta-analysis
Meta-analysis associates childhood antibiotic use with increased inflammatory bowel disease risk Early antibiotics may raise your risk of developing inflammatory bowel disease later in life
This meta-analysis of 8 studies involving 2783 cases examines the association between antibiotic use in children aged 1 to 17 years and the …
New research shows that taking antibiotics during childhood could increase the chance of developing inflammatory bowel disease later in life
May 4, 2026
Systematic review links gut microbial metabolites to colitis-associated colorectal cancer risk
Gastroenterology Sys. Review
Systematic review links gut microbial metabolites to colitis-associated colorectal cancer risk Your Gut Bacteria Make Cancer Fighters or Fuel Inside You
This systematic review synthesizes evidence on gut microbial metabolites in colitis-associated colorectal cancer. Elevated plasma TMAO level…
• Gut chemicals either protect against or drive colon cancer growth • Helps people with inflammatory bowel disease facing high cancer risk •…
Frontiers May 4, 2026
Meta-analysis finds high anxiety and depression prevalence in pediatric inflammatory bowel disease
Psychiatry Meta-analysis
Meta-analysis finds high anxiety and depression prevalence in pediatric inflammatory bowel disease Anxiety and depression are common in young people with inflammatory bowel disease
This meta-analysis synthesized data on anxiety and depression in children and adolescents with inflammatory bowel disease. It found pooled p…
About one in eight young people with IBD have anxiety symptoms, and one in seven have depression symptoms, a new analysis shows.
May 2, 2026
Extended Risankizumab Benefits Initial Nonresponders in Ulcerative Colitis
Drug Pipeline RCT
Extended Risankizumab Benefits Initial Nonresponders in Ulcerative Colitis Over half of ulcerative colitis patients found relief with longer treatment
Over 50% of patients with ulcerative colitis who did not respond to initial risankizumab achieved clinical response with 12 more weeks of ex…
More than half of patients with ulcerative colitis who did not respond to initial treatment found clinical response with extended risankizum…
May 1, 2026
Narrative review discusses NF-kB inhibition for inflammatory bowel diseases and related conditions
Gastroenterology Sys. Review
Narrative review discusses NF-kB inhibition for inflammatory bowel diseases and related conditions Blocking NF-κB May Ease Gut Inflammation in IBD
This narrative review explores the role of NF-kB pathway inhibition in treating inflammatory conditions.
A review finds that blocking a key inflammatory pathway could help treat Crohn's, colitis, and celiac disease.
Frontiers May 1, 2026
Systematic review shows regional differences in HS comorbidity prevalence across North America, Europe, and Asia
Dermatology Meta-analysis
Systematic review shows regional differences in HS comorbidity prevalence across North America, Europe, and Asia Regional differences in health risks for hidradenitis suppurativa patients
This systematic review and meta-analysis examines the prevalence of hidradenitis suppurativa-associated comorbidities across North America, …
A meta-analysis reveals how hidradenitis suppurativa patients in North America, Europe, and the Middle East/Asia face different odds for dia…
May 1, 2026

Questions about Inflammatory Bowel Disease

How does oral microbial diversity in Crohn's disease compare to people without the condition?

People with Crohn's disease have significantly lower oral microbial diversity compared to healthy individuals, with specific bacterial shifts and reduced butyrate metabolism.

Full answer →
Can enteral nutrition therapy help achieve remission for Chinese patients with inflammatory bowel disease?

Yes, enteral nutrition therapy can help achieve remission in Chinese IBD patients, with a 60% clinical remission rate over 6 weeks, especially in Crohn's disease.

Full answer →
What is the link between gut microbial metabolites and colorectal cancer risk in inflammatory bowel disease?

Gut microbial metabolites like short-chain fatty acids protect against colorectal cancer in IBD, while secondary bile acids, TMAO, and hydrogen sulfide promote it.

Full answer →
How does childhood antibiotic use affect the risk of developing inflammatory bowel disease?

Childhood antibiotic use is linked to a higher risk of developing inflammatory bowel disease, with a meta-analysis showing a 42% increased risk overall.

Full answer →